CA

CanBas Co.,Ltd.

A clinical-stage biopharmaceutical company developing novel cancer therapeutics.

4575 | T

Overview

Corporate Details

ISIN(s):
JP3244570002
LEI:
Country:
Japan
Address:
沼津市大手町二丁目2番1号

Description

CanBas is a clinical-stage biopharmaceutical company dedicated to the research and development of novel therapeutics for cancer patients. The company focuses on drug discovery in the field of oncology, including immuno-oncology and treatments targeting the cell cycle. Its pipeline includes CBP501, a calmodulin-modulating peptide that has undergone Phase II clinical trials. CanBas leverages proprietary screening systems and core technologies to develop innovative anti-cancer agents, with a focus on creating treatments with potentially fewer side effects.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-09-26 08:07
内部統制報告書-第24期(2023/09/25-2023/09/25)
Japanese 21.7 KB
2023-09-26 08:06
確認書
Japanese 8.1 KB
2023-09-26 08:05
有価証券報告書-第24期(2022/07/01-2023/06/30)
Japanese 683.0 KB
2023-05-12 08:28
四半期報告書-第24期第3四半期(2023/01/01-2023/03/31)
Japanese 149.4 KB
2023-05-12 08:28
確認書
Japanese 8.1 KB
2023-02-10 07:22
確認書
Japanese 8.1 KB
2023-02-10 07:21
四半期報告書-第24期第2四半期(2022/10/01-2022/12/31)
Japanese 175.9 KB
2022-11-11 07:28
確認書
Japanese 8.2 KB
2022-11-11 07:27
四半期報告書-第24期第1四半期(令和4年7月1日-令和4年9月30日)
Japanese 154.2 KB
2022-09-27 08:03
内部統制報告書-第23期(令和3年7月1日-令和4年6月30日)
Japanese 21.7 KB
2022-09-27 08:03
確認書
Japanese 8.1 KB
2022-09-27 08:02
有価証券報告書-第23期(令和3年7月1日-令和4年6月30日)
Japanese 655.2 KB
2022-05-16 02:38
四半期報告書-第23期第3四半期(令和4年1月1日-令和4年3月31日)
Japanese 144.5 KB
2022-02-10 07:12
四半期報告書-第23期第2四半期(令和3年10月1日-令和3年12月31日)
Japanese 176.0 KB
2021-11-11 07:45
四半期報告書-第23期第1四半期(令和3年7月1日-令和3年9月30日)
Japanese 203.9 KB

Automate Your Workflow. Get a real-time feed of all CanBas Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CanBas Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CanBas Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.